congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
A health-related quality of life (QOL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) versus capecitabine (CAP) in patients with hormone receptor–positive (HR+), HER2-low metastatic breast cancer (mBC)
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)
Oral
T-DXd
ASCO 2024 | May 31 - June 4, 2024
A randomized study comparing electronic patient-reported outcomes monitoring with routine follow-up during trastuzumab deruxtecan treatment for inoperable or metastatic breast cancer patients: PRO-DUCE study
Poster
T-DXd
Miami Breast 2024 | March 7-10, 2024
Addressing barriers to identifying HER2-low metastatic breast cancer patients in a large
community oncology practice
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
An open-label, interventional, multicenter study of trastuzumab deruxtecan monotherapy in patients with unresectable and/or metastatic HER2-low or HER2 immunohistochemistry 0 breast cancer: DESTINY-Breast15
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Attrition rates from first- to third-line therapy in HER2+ metastatic breast cancer in Europe
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Blocking soluble TNF to improve potency of trastuzumab deruxtecan by increasing internalization and antitumor innate immune response in a resistant HER2-positive breast cancer model
Poster
T-DXd
AACR 2024 | April 5-10, 2024
Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: First phase of a large-scale, multicenter global ring study
Oral
Dato-DXd
JSMO 2024 | February 22-24, 2024
Dato-DXd vs chemotherapy for patients with inoperable/metastatic HR+/HER2– breast cancer: TROPION-Breast01 East Asian subset analysis